blinatumomab
FDA Authorizes Adaptive Biotechnologies NGS Test for Minimal Residual Disease
In granting de novo premarket authorization to ClonoSeq, the agency established its regulatory expectations for similar tests.
In granting de novo premarket authorization to ClonoSeq, the agency established its regulatory expectations for similar tests.